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Abstract: Commercially available platforms to stabilize messenger RNA (mRNA) and microRNA are critically designed to   optimize 
and ensure the quality and integrity of those nucleic acids. This is not only essential for gene expression analyses, but would   provide tech-
nical utility in providing concordant standard operating procedures in preserving the structural integrity of RNA species in   multicenter 
clinical research programs and biobanking of cells or tissues for subsequent isolation of intact RNA. The major challenge is that the 
presence of degraded samples may adversely influence the interpretation of expression levels on isolated mRNA or microRNA samples 
and that in the absence of a concordant operating procedure between multiple collaborating research centers would confound data analy-
sis and interpretation. However, in this issue of Biomarker Insights, Weber et al provide a detailed and critical analysis of two common 
RNA preservation systems, PAXgene and RNAlater. Such studies are lacking in the literature. However, the authors provide compelling 
evidence that not all conservation platforms are created equal and only one system proves its worth.
Keywords: nucleic acid, RNA, microRNA, proteomics, gene expression,Williams
140  Biomarker Insights 2010:5
Introduction—stabilizing the code
Since  the  discovery  of  nucleic  acids  by 
Friedrich   Miescher in 1868, which he referred to as 
“nuclein”,1  there  has  been  an  unprecedented  level 
of both   discovery and functional appreciation in our 
  understanding of RNA.2–6 The pivotal role played by 
RNA in protein synthesis and the biochemical mech-
anisms of RNA synthesis has been already worked 
out in the late 1930’s and 1950’s.2,3 Since then, RNA 
  species  have  been  sequenced.4  and  the  process  of 
gene  sequences  dampening  other  genes  has  been 
  discovered—a  process  known  as  gene  silencing.5 
Regulatory  RNA  sequences  such  as  microRNAs 
(miRNA) are post-transcriptional gene regulators that 
function to silence messenger RNA (mRNA). What 
  distinguishes miRNA from mRNA are that they are 
quite short RNA species, usually only 22   nucleotides 
in length, and as such are remarkably more   susceptible 
to  degradation  than  other  RNA    species  such  as 
mRNA.
It was not until the late 1990’s and 2000’s that 
miRNA were appreciated as a unique subgroup of 
conserved molecular regulators capable of repress-
ing many hundreds of mRNAs.6,7 The importance of 
miRNA in biological systems is pivotal since specific 
groups  of  miRNAs  exert  both  negative  and  posi-
tive gene regulatory functions. It is no surprise then 
that mRNA species are thought to be tightly regulated 
by miRNA in a cell type and tissue/organ type specific 
manner and are likely to be involved in almost every 
biological or physiological process and in health as 
well as disease states.8–10
Isolation of highly pure intact mRNA and miRNA 
is  critical  for  the  successful  quantification  of  the 
expression of those RNA species. In cancer research 
for example, cellular and tissue profiling requires 
precise quantification of mRNA and miRNA expres-
sion.  Fortunately,  the  tools  for  such  expression 
profiling are readily available and include reverse 
transcription polymerase chain reaction (RT-PCR), 
quantitative real-time RT-PCR (qRT-PCR) as well 
as multiplex gene expression quantification arrays 
that permit simultaneous gene-expression analysis 
of disease- or molecular-pathway specific gene set 
matrices.  However,  despite  such  methodological 
platforms  being  widely  available  commercially 
or having been developed as a standard operating 
  procedure (SOP) in the molecular biological research 
laboratory, the quality and integrity of the input RNA 
is a crucial variable that can not and should not be 
compromised.
The  quality  of  gene  expression  data  analyses 
obtained  by  the  experimental  platforms  described 
above,  are  stringently  dependent  on  the  integrity 
and  stability  of  the  mRNA  isolated  and  purified 
extracted from the tissue or population of adherent 
or suspension cell populations. This is of course also 
dependent proper optimal processing of the tissue or 
cellular on samples. The main concern in isolating 
highly pure and intact RNA is the exquisitely fragile 
nature of mRNA and miRNA and their susceptibil-
ity to   degradation by RNAses during the isolation 
procedure. Though many other variables such as the 
source of RNA (cultured cells versus primary cells or 
tissue; hypoxic environment versus normoxic envi-
ronment; good laboratory technique in handling RNA 
and so on) all play a role in retaining the intactness 
of RNA species during the isolation and purification 
  procedure, there are   commercially available tools to 
assist the investigator in preserving the intactness of 
RNA prior to   subsequent extraction and purification.
Methods to preserve RnA 
prove Their Worth
The main challenge in the laboratory is the ubiquitous 
presence  of  RNAses—robust  enzymes  that  can 
quickly and efficiently degrade purified RNA species. 
RNAses are present in both eukaryotes and prokary-
otes, indeed almost every cell type in humans express 
RNAses, in part because of their microbicidal proper-
ties and their important role in nucleic acid metabo-
lism. Standard practice in the research laboratory can 
minimize or avoid degradation of the purified RNA 
or miRNA species. This includes such basic consid-
erations as good aseptic techniques during all down-
stream processes,   ensuring materials and reagents that 
come into contact with RNA are RNAses-free, use 
of high-quality sterile plasticware that is guaranteed 
free of RNAses, frequent changes of nitrile gloves, 
and  use  of  respirator-type  dust  masks  and  other 
personal protective equipment (PPE) can markedly 
dampen the risk of contamination from human skin, 
perspiration, tears, saliva and so on. Thus, methods 
to control RNAse contamination in the laboratory are rnA stability procedures
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essential. Other useful laboratory precautions when 
handling mRNA and miRNA include pre-treatment 
of benchtops, pipetting devices, test tube racks and 
so on with a proprietary reagent called RNAseZap. 
In addition, water used for buffer preparations and 
solubilization of RNA should be RNAse-free or at 
least be treated with   diethylpyrocarbonate (DEPC) 
though one needs to be particularly careful in match-
ing buffer   compatibility with the use of DEPC in 
the  laboratory.  For  example,  this  would  include 
  buffers containing primary amine groups like Tris or 
those containing secondary and tertiary amines like 
HEPES. Such buffers can not be DEPC treated since 
they consume active DEPC quite quickly. However, 
alternative  reagents  can  be  used  for  inactivating 
RNAses in solution. One such reagent is RNAse-
cure resuspension solution which when introduced 
to a buffer or even purified RNA pellets can inacti-
vate RNAses. By heating the buffer or other biologi-
cal reagent solution to 60 °C for about 10 minutes, 
RNAsecure is “activated” and can thus be used to 
destroy RNAses introduced to a   buffer or reagent 
solution “post-treatment”.
However, in more complex situations such as in 
laser capture microdissection (LCM) analysis, main-
taining  or  even  guaranteeing  high  quality  RNA  in 
the  microscopic  isolation  of  cells  for  LCM  analy-
ses provides an additional challenge.11–13 Analysis of 
gene expression by LCM requires the precise isola-
tion of highly pure microscopic populations of cells 
from a quite heterogeneous tissue or organ source for 
subsequent purification of the RNA.14 The problem 
with LCM is that RNA degradation occurs rapidly 
and  frequently  such  that  reliable  gene  expression 
analyses of the transcriptome of interest are severely 
compromised.15,16 While frozen sections assist in the 
recovery of intact RNA,17 use of fixatives and the 
chemical components contained within them as well 
as staining reagents can adversely affect RNA sta-
bility and integrity. For such techniques, often quite 
sophisticated, investigator-initiated protocols need to 
be applied.18
In this issue of Biomarker Insights, Weber et al, 
have critically assessed the stabilization of mRNA 
and miRNA species using human peripheral blood 
samples and two common platforms for RNA pres-
ervation:  PAXgene  and  RNAlater.19  The  authors 
point out that a major goal in cancer research and 
related  clinical  trial  programs  is  the  identifica-
tion  and  validation  of  certain  tumor-associated 
  biomarkers in biological samples that can be read-
ily accessed such as peripheral venous blood. One 
of the key challenges of such biomarker discovery 
is the multi-center approach to such research. This 
provides the challenge of time and distance vari-
ables from the point at which samples are accessed, 
for example from participating study centers to the 
point where samples will bio- or tissue-banked for 
subsequent analyses. The main concern is that not 
all study centers participating in such a multi-center 
collaborative group have access to the expertise and 
necessary equipment that would permit extraction 
of intact, quality RNA species. Under such circum-
stances, it would be an appropriate additional step 
to focus the receipt of such samples to a common 
receiving laboratory that would have in place a con-
cordant and reliable SOP for the extraction and puri-
fication of RNA species common to all participating 
study centers. This obvious step would remove one of 
the major variables that may otherwise   compromise 
gene expression data analysis between collaborating 
laboratories.
In their study, Weber et al compared the utility of 
two  common  RNA  preservation  methods,  namely 
PAXgene and RNAlater, both of which are commer-
cially available.19 Both platforms are capable of sta-
bilizing RNA and providing the advantage that RNA 
species need not be isolated immediately on sampling 
a peripheral blood specimen from a study subject. 
While PAXgene has traditionally been employed for 
stabilization of RNA in human venous blood samples 
and particularly of mRNA,20,21 it is less clear whether 
PAXgene stabilized venous blood similarly stabilizes 
the structural integrity of miRNA species. However, 
it has been reported that PAXgene fails to adequately 
stabilize specific gene transcripts, at least under par-
ticular circumstances.22 For this reason, Weber et al 
explored the utility of the RNAlater system—a rela-
tively  common  stabilizing  system  for  studies  that 
require intact RNA for gene expression analyses and 
biobanking. In a comparative analysis, Weber et al 
assessed the relative merits of both the PAXgene sys-
tem and the RNAlater platform for RNA stabilization 
in human peripheral venous blood.Williams
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In  a  very  well  controlled  and  designed  study, 
Weber  et  al  tested  both  systems  on  freshly  drawn 
anticoagulated blood held at ambient or room tem-
perature, as well as blood samples that were anticoag-
ulated and held on dry ice without storage at −80 °C, 
or anticoagulated and held on dry ice with storage 
at −80 °C for a period of 6 months prior to RNA iso-
lation. All samples were sent to a central receiving 
laboratory  by  overnight  courier  service  or  regular 
mail and RNA isolated immediately or 6 months later 
for the samples held at −80 °C.
Weber et al found that the RNAlater system proved 
its worth in maintaining RNA integrity.19 By assessment 
of RNA yields, RNAlater was found to be superior to 
PAXgene. Although  this  may  have  been  caused  by 
deviation from the manufacturer’s protocol, the same 
variables were true for both RNA stabilization systems. 
One of the key quantitative measures that demonstrated 
the superior ability of RNAlater to preserve RNA integ-
rity was by virtue of the RIN value, where a RIN value 
of .8 is considered optimal for downstream expression 
analyses. Peripheral venous blood samples stabilized 
in RNAlater consistently gave RIN values .8, while 
PAXgene  was  somewhat  more  variable.  However, 
in terms of stabilizing mRNA, it was found that irre-
spective of shipping conditions (ambient versus frozen 
temperatures), both RNAlater and PAXgene performed 
equally well when assessing the expression of a single 
gene  transcript,  namely  ATM  (ataxia-telangiectasia 
mutated gene) by RT-PCR analysis.
Importantly, the authors point out that, similar to 
the challenges of mRNA integrity, the stabilization of 
miRNA species is variable, particularly with regard 
the stability of miRNA-26a and miRNA-26b.19 Thus, 
not only is the choice of stabilization system impor-
tant, but the choice of isolation and purification system 
for miRNA may differ somewhat from that optimized 
for mRNA isolation. However, despite some superior 
indices of yield and integrity of isolated mRNA and 
miRNA species using the RNAlater system, unlike 
the PAXgene system, there is currently no approved 
system of RNAlater containing vacutainer tubes used 
for collection of peripheral blood and stabilization of 
RNA. This additional step of introducing RNAlater 
to the collected blood sample runs the risk of cross-
contamination of the sample as well as the research 
study personnel.
conclusion
The RNAlater system provides a feasible alternative 
to the conventional use of PAXgene. However, much 
work is still required to properly validate and confirm 
the effectiveness of RNAlater in preserving a broad 
spectrum of mRNA and miRNA transcripts. Addi-
tionally, the broad clinical and research study utility 
of RNAlater for preserving RNA stability in human 
peripheral venous blood in multi-center clinical trials 
and collaborating groups requires thorough valida-
tion in double-blinded research studies.
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